|
全民健康保險藥品給付規定 / 健保碼及健保價 |
|
See related Emend cap[止敏吐 膠囊] information |
|
|
|
製造商 |
Merck Sharp & Dohme |
|
代理/經銷商 |
Merck Sharp & Dohme |
|
成份 |
Aprepitant |
|
適應症 |
Prevention of acute & delayed nausea & vomiting associated with initial & repeat courses of highly & moderately emetogenic cancer chemotherapy. |
|
用量 |
Given as part of a 3-day regimen that includes a corticosteroid & a 5-HT3 antagonist. Recommended dose: 125 mg orally 1 hr prior to chemotherapy (day 1) & 80 mg once daily in the morning on days 2 & 3. |
|
過量 |
View Emend[止敏吐] overdosage for action to be taken in the event of an overdose. |
|
用法 |
May be taken with or without food |
|
美國食品藥物管理局之懷孕等級 |
Category B: Either animal-reproduction studies have not demonstrated a foetal risk but there are no controlled studies in pregnant women or animal-reproduction studies have shown an adverse effect (other than a decrease in fertility) that was not confirmed in controlled studies in women in the 1st trimester (and there is no evidence of a risk in later trimesters). |
|
禁忌 |
Concurrent administration with pimozide, terfenadine, astemizole, or cisapride. |
|
注意事項 |
Patients receiving concomitant medications that are primarily metabolized through CYP3A4. Patients on chronic warfarin therapy should have their INR closely monitored in the 2-week period, particularly at 7-10 days, following initiation of therapy. Concomitant administration may reduce the efficacy of OCs. Pregnancy, lactation. |
|
不良反應 |
Hiccups, asthenia/fatigue, ALT increased, constipation, headache, anorexia.
View ADR Monitoring Website[參閱藥物不良反應監測表格] |
|
副作用 |
View Emend[止敏吐] side effects |
|
交互作用 |
Avoid concurrent administration with pimozide, terfenadine, astemizole, or cisapride. May lower the plasma concentration of concomitantly administered S(-) warfarin, tolbutamide & phenytoin. The usual dose of dexamethasone & methylprednisolone should be reduced. Caution & close monitoring advised when co-administered with chemotherapeutic agents (etoposide, vinorelbine, docetaxel & paclitaxel). Patients on chronic warfarin therapy should have their INR closely monitored in the 2-week period, particularly at 7-10 days, following initiation of therapy. May reduce efficacy of concomitant OC. May increase plasma concentration of benzodiazepines metabolized via CYP3A4 (midazolam, triazolam & alprazolam). Caution when used together with strong CYP3A4 inhibitors eg ketoconazole; rifampin; paroxetine.
View more drug interactions with Emend[止敏吐] |
|
儲存 |
View Emend[止敏吐] storage conditions for details to ensure optimal shelf-life. |
|
描述 |
View Emend[止敏吐] description for details of the chemical structure and excipients (inactive components). |
|
作用 |
View Emend[止敏吐] mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
本商品之市售規格 |
|
劑型 |
包裝 |
圖片 |
|
Emend 膠囊 |
|
Emend 80 mg x 1's |
 |
|
Emend 125 mg x 1's |
 |
|
|
|
Manufacturer: |
Merck Sharp & Dohme |
|
Distributor: |
Merck Sharp & Dohme |
|
|
|
|
|
